DB
DGX icon

Dmitry Balyasny’s Quest Diagnostics DGX Stock Holding History

Dmitry Balyasny’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-55,000
Closed -$5.42M – 2009
2017
Q4 		$5.42M Buy
+55,000
New +$5.21M 0.02% 832

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Dmitry Balyasny's DGX Position: Q2 2026 in Review

Dmitry Balyasny increased its Quest Diagnostics (DGX) stake by 9,402% in Q2 2026, buying an estimated $53.5M and bringing the position to 275,371 shares worth $58.4M. The position accounts for 0.07% of the portfolio, ranked #321.

Dmitry Balyasny first reported a position in DGX in Q2 2013 and has held it in 31 quarters since. The position peaked at $78.3M in Q2 2022. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Dmitry Balyasny held 275,371 shares of Quest Diagnostics worth $58.4M as of Q2 2026.
  • Dmitry Balyasny bought 272,473 Quest Diagnostics shares in Q2 2026, an estimated $53.5M.
  • Quest Diagnostics made up 0.07% of Dmitry Balyasny's portfolio in Q2 2026, its #321 holding.
  • Dmitry Balyasny first reported a position in Quest Diagnostics in Q2 2013 and has held it in 31 quarters since.
  • Dmitry Balyasny's Quest Diagnostics position peaked at $78.3M in Q2 2022.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.